Peer group selection
We have rapidly evolved and will continue to evolve into a fully integrated immunology company with a strong presence globally. To thrive and continue building the organization, we need executive and nonexecutive talent with a deep understanding of the global market in which we operate. We therefore compete for global talent. This is why we have established a global peer group focused on six key criteria that reflect the companies we benchmark against in attracting and retaining top talent.
In connection with the benchmark exercise for 2025 remuneration ahead of setting fixed and variable pay levels, the following criteria were used for the first time in the third quarter of 2024 to select the new global peer group (the Peer Group).
Compared to the European and Global peer groups used for the determine of the remuneration until 2024, the 2025 Peer Group consists of 15 companies. We deem a minimum of 15 companies appropriate, because (i) our industry tends to evolve quickly, with companies emerging and disappearing (due to mergers or otherwise) relatively often, and (ii) we deem it relevant to have a certain consistency in the companies comprising our peer group over the longer term.
If there are not 15 companies meeting each of the criteria, we will include in our reference group all companies that meet the criteria, and supplement with companies that meet all but one criterion. The least relevant criterion will be dropped first, in the order as displayed below (from most to least relevant).
Selection Criterion |
|
Range of Peers based on Criterion |
|
Relevance of criterion |
||||
---|---|---|---|---|---|---|---|---|
1. Sector |
|
Biopharmaceutical companies, excluding diagnostics and animal health companies |
|
Biopharmaceutical companies have characteristic pay and incentive structures compared to other industries. |
||||
2. Listing location |
|
Listed on a major US Stock Exchange |
|
Being listed on a major US stock exchange brings additional complexity, expertise requirements and potential liabilities to company officers and directors, which is typically reflected in a different pay structure of executives and board members serving on US listed companies, versus companies without a US listing. Our benchmark exercise shows that having a listing on a major US stock exchange tends to have a more significant relevance for pay structure applied by companies than does location of headquarters, which is why we do not apply a ‘location of headquarters’ filter. |
||||
3. Innovation focus |
|
At least 25% of revenue is spent on R&D |
|
Innovation focused, R&D driven companies tend to have a typical remuneration structure which differs from companies who focus on commercializing external innovations. |
||||
4. Global reach |
|
Generates product revenues both within and outside the US |
|
Leading commercial operations both inside and outside the United States puts unique demands on the skills and expertise of key individuals, in addition to the strain of splitting their time and efforts across continents. For this reason, we compare pay practices to other global companies instead of companies with mostly local activities. |
||||
5. Revenue |
|
1/4 – 4x of our annual revenue |
|
We compare ourselves to organizations that also have significant product revenues, as a reflection of overall size and complexity of the organization. Using a relatively wide range for this metric is appropriate to ensure we include relevant peers while ensuring a level of stability in the peer group over time. In setting the range, we also considered the rapid development in our own revenues since our first year of product commercialization (2023) and our internal revenue projections for the immediate future. |
||||
6. Market Cap |
|
1/4 – 4x our market cap (based on 30 day average closing price) |
|
Whereas market cap can give some indication of overall size and complexity of comparator organizations, we also recognize that companies in our sector tend to have volatile stock prices and market cap can vary significantly even throughout a given calendar year.1) |
||||
|
Company Name |
|
Country of Headquarters |
---|---|---|
Alnylam Pharmaceuticals, Inc. |
|
USA |
Amicus Therapeutics, Inc. |
|
USA |
Ascendis Pharma A/S |
|
Denmark |
BeiGene, Ltd. |
|
Cayman Islands |
Biogen Inc. |
|
USA |
BioMarin Pharmaceutical Inc. |
|
USA |
BioNTech SE |
|
Germany |
Blueprint Medicines Corporation |
|
USA |
Genmab SE |
|
Denmark |
Incyte Corporation |
|
USA |
Insmed Inc. |
|
USA |
Jazz Pharmaceuticals plc |
|
Ireland |
Moderna, Inc. |
|
USA |
Sarepta Therapeutics, Inc. |
|
USA |
Ultragenyx Pharmaceutical Inc. |
|
USA |